Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | HAVCR2 | Q8TDQ0 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565459 | 0.91 | MET (0.49) | HPGDUSP2POLBALOX12HSD17B10 | |
| SCHEMBL20565140 | 0.83 | KDM4E (0.42) | HPGDUSP2POLBALOX12HSD17B10 | |
| SCHEMBL20565123 | 0.82 | GSK3A (0.41) | HPGDUSP2POLBALOX12HSD17B10 | |
| SCHEMBL20565557 | 0.80 | MET (0.45) | HPGDUSP2POLBALOX12HSD17B10 | |
| SCHEMBL20565109 | 0.80 | DYRK1A (0.42) | HPGDUSP2POLBALOX12HSD17B10 | |
| SCHEMBL20564460 | 0.80 | DYRK1A (0.40) | HPGDUSP2POLBALOX12HSD17B10 | |
| SCHEMBL23630453 | 0.80 | HPGD (0.43) | HPGDUSP2POLBALOX12HSD17B10 | |
| SCHEMBL23630305 | 0.79 | CNR1 (0.44) | HPGDUSP2POLBALOX12HSD17B10 | |
| SCHEMBL20564874 | 0.78 | CA9 (0.43) | HPGDKDM4ELMNAMEN1KMT2A | |
| SCHEMBL20565458 | 0.78 | AS3MT (0.49) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200148687-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200148687-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3624805-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | Kapoor, Tarun, M. (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018213712-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | KAPOOR TARUN M (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148687-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | HPGD 686/4885USP2 4015/4885POLB 1966/4885 |
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | HPGD 686/4885USP2 4015/4885POLB 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.